{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T00:17:36Z","timestamp":1778545056331,"version":"3.51.4"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2018-0139_s_999_w2aab3b7c60b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Recombinant human insulin-like growth factor 1 (rhIGF-I) has been approved as an orphan drug for the treatment of growth failure in children and adolescents with severe primary IGF-I deficiency (SPIGFD) with little pharmacokinetic data available. Therefore, sequential measurements of serum IGF-I, glucose, potassium, insulin and cortisol were performed in patients treated with rhIGF-I to evaluate their significance in safety and efficacy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0139_s_998_w2aab3b7c60b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Repetitive blood samples were taken after meals before and 30, 60, 120, 180 and 360 min after rhIGF-I injections in two male patients with Laron syndrome at times of dose adjustments.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0139_s_997_w2aab3b7c60b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Maximal IGF-I concentrations were observed 2 h after injections (495 ng\/mL) and concentrations were still higher 6 h after injections than at baseline (303 ng\/mL vs. 137 ng\/mL). Thirteen percent of all and 33% of maximum IGF-I concentrations were greater than +2 standard deviation score (SDS) calculated for bone age (BA) (IGF-I SDS BA) rather than chronological age (CA) as BA was significantly delayed to CA by 3.2 years (p=0.0007). Height velocities correlated with individual maximum IGF-I SDS BA (\u03c1=0.735; p&lt;0.0001). Serum insulin, cortisol and glucose did not correlate with IGF-I concentrations, but serum potassium showed a negative correlation (\u03c1=\u22120.364; p&lt;0.0001) with IGF-I concentrations.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2018-0139_s_996_w2aab3b7c60b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Sequential measurements of serum IGF-I, glucose and potassium in patients with Laron syndrome may aid in optimizing and individualizing rhIGF-I treatment. IGF-I concentrations should be referenced according to BA which better reflects the biological age. The inverse correlation of IGF-I and serum potassium concentrations after injections of rhIGF-I has not been reported before and warrants further consideration.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2018-0139","type":"journal-article","created":{"date-parts":[[2018,7,12]],"date-time":"2018-07-12T22:55:40Z","timestamp":1531436140000},"page":"895-902","source":"Crossref","is-referenced-by-count":3,"title":["Sequential measurements of IGF-I serum concentrations in adolescents with Laron syndrome treated with recombinant human IGF-I (rhIGF-I)"],"prefix":"10.1515","volume":"31","author":[{"given":"Thomas","family":"Breil","sequence":"first","affiliation":[{"name":"Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics , University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carolin","family":"Kneppo","sequence":"additional","affiliation":[{"name":"Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics , University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Bettendorf","sequence":"additional","affiliation":[{"name":"Division of Paediatric Endocrinology and Diabetes, Department of Paediatrics , University Hospital Heidelberg , Heidelberg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hermann L.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"Department of Paediatrics and Paediatric Haematology\/Oncology , Klinikum Oldenburg A\u00f6R, Medical Campus University Oldenburg , Oldenburg , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaus","family":"Kapelari","sequence":"additional","affiliation":[{"name":"Department of Paediatric Endocrinology , University of Innsbruck , Innsbruck , Austria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Schnabel","sequence":"additional","affiliation":[{"name":"Center for Chronically Sick Children, Paediatric Endocrinology, Charit\u00e9 , University Medicine Berlin , Berlin , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joachim","family":"Woelfle","sequence":"additional","affiliation":[{"name":"Division of Paediatric Endocrinology , Children\u2019s Hospital, University of Bonn , Bonn , Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,7,11]]},"reference":[{"key":"2023040101280976209_j_jpem-2018-0139_ref_001_w2aab3b7c60b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Laron Z. Laron syndrome (primary growth hormone resistance or insensitivity): the personal experience 1958\u20132003. J Clin Endocrinol Metab 2004;89:1031\u201344.","DOI":"10.1210\/jc.2003-031033"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_002_w2aab3b7c60b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Wit JM, Oostdijk W, Losekoot M. Spectrum of insulin-like growth factor deficiency. Endocr Dev 2012;23:30\u201341.","DOI":"10.1159\/000341739"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_003_w2aab3b7c60b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Laron Z. Lessons from 50 years of Study of Laron Syndrome. Endocr Pract 2015;21:1395\u2013402.","DOI":"10.4158\/EP15939.RA"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_004_w2aab3b7c60b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Pantel J, Grulich-Henn J, Bettendorf M, Strasburger CJ, Heinrich U, et al. Heterozygous nonsense mutation in exon 3 of the growth hormone receptor (GHR) in severe GH insensitivity (Laron syndrome) and the issue of the origin and function of the GHRd3 isoform. J Clin Endocrinol Metab 2003;88:1705\u201310.","DOI":"10.1210\/jc.2002-021667"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_005_w2aab3b7c60b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Laron Z. Emerging treatment options for patients with Laron syndrome. Expert Opin Orphan Drugs 2014;2:681\u201394.","DOI":"10.1517\/21678707.2014.912581"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_006_w2aab3b7c60b1b6b1ab2b2b6Aa","doi-asserted-by":"crossref","unstructured":"Ranke MB, Wolfle J, Schnabel D, Bettendorf M. Treatment of dwarfism with recombinant human insulin-like growth factor-1. Dtsch Arztebl Int 2009;106:703\u20139.","DOI":"10.3238\/arztebl.2009.0703"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_007_w2aab3b7c60b1b6b1ab2b2b7Aa","doi-asserted-by":"crossref","unstructured":"Ranke MB. Treatment with recombinant human insulin-like growth factor-1 in severe primary IGF deficiency and beyond. Horm Res Paediatr 2015;83:358\u201360.","DOI":"10.1159\/000380851"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_008_w2aab3b7c60b1b6b1ab2b2b8Aa","doi-asserted-by":"crossref","unstructured":"Backeljauw PF, Kuntze J, Frane J, Calikoglu AS, Chernausek SD. Adult and near-adult height in patients with severe insulin-like growth factor-I deficiency after long-term therapy with recombinant human insulin-like growth factor-I. Horm Res Paediatr 2013;80:47\u201356.","DOI":"10.1159\/000351958"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_009_w2aab3b7c60b1b6b1ab2b2b9Aa","doi-asserted-by":"crossref","unstructured":"Keating GM. Mecasermin. BioDrugs 2008;22:177\u201388.","DOI":"10.2165\/00063030-200822030-00004"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_010_w2aab3b7c60b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Cohen J, Blethen S, Kuntze J, Smith SL, Lomax KG, et al. Managing the child with severe primary insulin-like growth factor-1 deficiency (IGFD): IGFD diagnosis and management. Drugs R D 2014;14:25\u20139.","DOI":"10.1007\/s40268-014-0039-7"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_011_w2aab3b7c60b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Pfaffle R. Hormone replacement therapy in children: the use of growth hormone and IGF-I. Best Pract Res Clin Endocrinol Metab 2015;29:339\u201352.","DOI":"10.1016\/j.beem.2015.04.009"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_012_w2aab3b7c60b1b6b1ab2b2c12Aa","unstructured":"Laron Z. If one daily injection of IGF-I has the same growth-promoting effect as 2 injections per day, why continue to give two injections? Pediatric Endocrinol Rev: PER 2013;10:277\u20139."},{"key":"2023040101280976209_j_jpem-2018-0139_ref_013_w2aab3b7c60b1b6b1ab2b2c13Aa","doi-asserted-by":"crossref","unstructured":"Midyett LK, Rogol AD, Van Meter QL, Frane J, Bright GM, et al. Recombinant insulin-like growth factor (IGF)-I treatment in short children with low IGF-I levels: first-year results from a randomized clinical trial. J Clin Endocrinol Metab 2010;95:611\u20139.","DOI":"10.1210\/jc.2009-0570"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_014_w2aab3b7c60b1b6b1ab2b2c14Aa","doi-asserted-by":"crossref","unstructured":"Chernausek SD, Backeljauw PF, Frane J, Kuntze J, Underwood LE, et al. Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficiency due to growth hormone insensitivity. J Clin Endocrinol Metab 2007;92:902\u201310.","DOI":"10.1210\/jc.2006-1610"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_015_w2aab3b7c60b1b6b1ab2b2c15Aa","doi-asserted-by":"crossref","unstructured":"Bang P, Polak M, Woelfle J, Houchard A, Group EIRS. Effectiveness and safety of rhIGF-1 therapy in children: the European Increlex(R) Growth Forum Database Experience. Horm Res Paediatr 2015;83:345\u201357.","DOI":"10.1159\/000371798"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_016_w2aab3b7c60b1b6b1ab2b2c16Aa","doi-asserted-by":"crossref","unstructured":"Fintini D, Brufani C, Cappa M. Profile of mecasermin for the long-term treatment of growth failure in children and adolescents with severe primary IGF-1 deficiency. Ther Clin Risk Manag 2009;5:553\u20139.","DOI":"10.2147\/TCRM.S6178"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_017_w2aab3b7c60b1b6b1ab2b2c17Aa","doi-asserted-by":"crossref","unstructured":"Cabrera-Salcedo C, Mizuno T, Tyzinski L, Andrew M, Vinks AA, et al. Pharmacokinetics of IGF-1 in PAPP-A2-deficient patients, growth response, and effects on glucose and bone density. J Clin Endocrinol Metab 2017;102:4568\u201377.","DOI":"10.1210\/jc.2017-01411"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_018_w2aab3b7c60b1b6b1ab2b2c18Aa","doi-asserted-by":"crossref","unstructured":"Hogler W, Martin DD, Crabtree N, Nightingale P, Tomlinson J, et al. IGFALS gene dosage effects on serum IGF-I and glucose metabolism, body composition, bone growth in length and width, and the pharmacokinetics of recombinant human IGF-I administration. J Clin Endocrinol Metab 2014;99:E703\u201312.","DOI":"10.1210\/jc.2013-3718"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_019_w2aab3b7c60b1b6b1ab2b2c19Aa","doi-asserted-by":"crossref","unstructured":"Vaccarello MA, Diamond FB, Jr., Guevara-Aguirre J, Rosenbloom AL, Fielder PJ, et al. Hormonal and metabolic effects and pharmacokinetics of recombinant insulin-like growth factor-I in growth hormone receptor deficiency\/Laron syndrome. J Clin Endocrinol Metab 1993;77:273\u201380.","DOI":"10.1210\/jcem.77.1.7686916"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_020_w2aab3b7c60b1b6b1ab2b2c20Aa","doi-asserted-by":"crossref","unstructured":"Klinger B, Garty M, Silbergeld A, Laron Z. Elimination characteristics of intravenously administered rIGF-I in Laron-type dwarfs. Dev Pharmacol Ther 1990;15:196\u20139.","DOI":"10.1159\/000457646"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_021_w2aab3b7c60b1b6b1ab2b2c21Aa","doi-asserted-by":"crossref","unstructured":"Clayton PE, Hall CM. Insulin-like growth factor I levels in healthy children. Horm Res 2004;62(Suppl 1):2\u20137.","DOI":"10.1159\/000080752"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_022_w2aab3b7c60b1b6b1ab2b2c22Aa","doi-asserted-by":"crossref","unstructured":"Tanner JM. Normal growth and techniques of growth assessment. Clin Endocrinol Metab 1986;15:411\u201351.","DOI":"10.1016\/S0300-595X(86)80005-6"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_023_w2aab3b7c60b1b6b1ab2b2c23Aa","doi-asserted-by":"crossref","unstructured":"Reinken L, van Oost G. Longitudinal physical development of healthy children 0 to 18 years of age. Body length\/height, body weight and growth velocity. Klin Padiatr 1992;204:129\u201333.","DOI":"10.1055\/s-2007-1025337"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_024_w2aab3b7c60b1b6b1ab2b2c24Aa","doi-asserted-by":"crossref","unstructured":"Brandt I, Reinken L. The growth rate of healthy children in the first 16 years: Bonn-Dortmund longitudinal developmental study. Klin Padiatr 1988;200:451\u20136.","DOI":"10.1055\/s-2008-1033752"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_025_w2aab3b7c60b1b6b1ab2b2c25Aa","doi-asserted-by":"crossref","unstructured":"Kromeyer-Hauschild KW, Kunze D, Geller F, Gei\u00df HC, Hesse V, et al. Perzentile f\u00fcr den Body-mass-Index f\u00fcr das Kindes- und Jugendalter unter Heranziehung verschiedener deutscher Stichproben. Monatsschr Kinderheilk 2001;149:807\u201318.","DOI":"10.1007\/s001120170107"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_026_w2aab3b7c60b1b6b1ab2b2c26Aa","doi-asserted-by":"crossref","unstructured":"Blum WF, Albertsson-Wikland K, Rosberg S, Ranke MB. Serum levels of insulin-like growth factor I (IGF-I) and IGF binding protein 3 reflect spontaneous growth hormone secretion. J Clin Endocrinol Metab 1993;76:1610\u20136.","DOI":"10.1210\/jcem.76.6.7684744"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_027_w2aab3b7c60b1b6b1ab2b2c27Aa","doi-asserted-by":"crossref","unstructured":"Bayley N, Pinneau SR. Tables for predicting adult height from skeletal age: revised for use with the Greulich-Pyle hand standards. J Pediatr 1952;40:423\u201341.","DOI":"10.1016\/S0022-3476(52)80205-7"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_028_w2aab3b7c60b1b6b1ab2b2c28Aa","doi-asserted-by":"crossref","unstructured":"Pini G, Congiu L, Benincasa A, DiMarco P, Bigoni S, et al. Illness severity, social and cognitive ability, and EEG analysis of ten patients with rett syndrome treated with mecasermin (Recombinant Human IGF-1). Autism Res Treat 2016;2016:5073078.","DOI":"10.1155\/2016\/5073078"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_029_w2aab3b7c60b1b6b1ab2b2c29Aa","doi-asserted-by":"crossref","unstructured":"Khwaja OS, Ho E, Barnes KV, O\u2019Leary HM, Pereira LM, et al. Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc Natl Acad Sci USA 2014;111:4596\u2013601.","DOI":"10.1073\/pnas.1311141111"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_030_w2aab3b7c60b1b6b1ab2b2c30Aa","doi-asserted-by":"crossref","unstructured":"Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016;86:361\u201397.","DOI":"10.1159\/000452150"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_031_w2aab3b7c60b1b6b1ab2b2c31Aa","doi-asserted-by":"crossref","unstructured":"Guevara-Aguirre J, Rosenbloom AL, Guevara-Aguirre M, Saavedra J, Procel P. Recommended IGF-I dosage causes greater fat accumulation and osseous maturation than lower dosage and may compromise long-term growth effects. J Clin Endocrinol Metab 2013;98:839\u201345.","DOI":"10.1210\/jc.2012-3704"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_032_w2aab3b7c60b1b6b1ab2b2c32Aa","doi-asserted-by":"crossref","unstructured":"Martin DD, Wit JM, Hochberg Z, Savendahl L, van Rijn RR, et al. The use of bone age in clinical practice \u2013 part 1. Horm Res Paediatr 2011;76:1\u20139.","DOI":"10.1159\/000329372"},{"key":"2023040101280976209_j_jpem-2018-0139_ref_033_w2aab3b7c60b1b6b1ab2b2c33Aa","doi-asserted-by":"crossref","unstructured":"Blum WF, B\u00f6ttcher C, Wudy SA in Ranke MB, Mullis P-E, editors. Diagnostics of endocrine function in children and adolescents, 4th ed. Basel: Karger, 2011:157\u201382.","DOI":"10.1159\/000327407"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2018.31.issue-8\/jpem-2018-0139\/jpem-2018-0139.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0139\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0139\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,1]],"date-time":"2023-04-01T20:11:51Z","timestamp":1680379911000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2018-0139\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,7,11]]},"references-count":33,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2018,7,9]]},"published-print":{"date-parts":[[2018,8,28]]}},"alternative-id":["10.1515\/jpem-2018-0139"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2018-0139","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,7,11]]}}}